Eisai and Biogen have announced that the FDA has approved LEQEMBI 100 mg/mL injection for intravenous use for treating Alzheimer's disease.| Labiotech.eu
Learn more about Biogen's strategic realignment from Aduhelm's controversy to Leqembi's promise in Alzheimer's treatment.| Labiotech.eu
As we observe Alzheimer's & Brain Awareness Month in June, here are six recent advancements that could transform Alzheimer's research.| Labiotech.eu